Research graph
References from Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
10.3322/caac.21660 · 2021 · External reference
Relationship between VEGF Family Members, Their Receptors and Cell Death in the Neoplastic Transformation of Colorectal Cancer
10.3390/ijms23063375 · 2022 · External reference
The biology of VEGF and its receptors
10.1038/nm0603-669 · 2003 · External reference
Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment
10.1111/cpr.13009 · 2021 · External reference
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
10.1038/362841a0 · 1993 · External reference
Vascular endothelial growth factor: basic science and clinical progress
10.1210/er.2003-0027 · 2004 · External reference
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(16)32453-9 · 2017 · External reference
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
10.1016/s1470-2045(08)70285-7 · 2009 · External reference
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
10.1016/s0140-6736(18)30207-1 · 2018 · External reference
Sorafenib in advanced hepatocellular carcinoma
10.1056/nejmoa0708857 · 2008 · External reference
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
10.1200/jco.21.00163 · 2021 · External reference
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s2468-1253(21)00109-6 · 2021 · External reference
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2021.0022 · 2021 · External reference
The adverse effects of sorafenib in patients with advanced cancers
10.1111/bcpt.12365 · 2015 · External reference
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
10.1007/s00262-022-03349-4 · 2023 · External reference
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
10.1016/j.critrevonc.2022.103596 · 2022 · External reference
Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis
10.1016/s1470-2045(18)30261-4 · 2018 · External reference
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing
10.2217/fon-2020-0669 · 2020 · External reference
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
2022 · External reference
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
Therapeutic efficacy of brucea javanica oil emulsion (BJOE) combined with transcatheter hepatic arterial chemoembolization (TACE) in patients with primary liver cancer
2015 · External reference
Fufang Banmao Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3-4 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment
10.1089/acm.2019.0334 · 2020 · External reference
Systematic evaluation of Huaier Granules adjuvant treatment of primary liver cancer
2021 · External reference
Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
10.1080/13880209.2020.1799040 · 2020 · External reference
Prospective randomized controlled study on advanced primary hepatic cancer treated by ganfule prescription
2014 · External reference
Inhibitory effects of nobiletin on hepatocellular carcinoma in vitro and in vivo
10.1002/ptr.5024 · 2014 · External reference
Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents
10.1016/j.apsb.2019.07.007 · 2020 · External reference
Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells
2013 · External reference
Huaier Restrains Proliferative and Migratory Potential of Hepatocellular Carcinoma Cells Partially Through Decreased Yes-Associated Protein 1
10.7150/jca.21018 · 2017 · External reference
Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1
10.1248/bpb.b18-00852 · 2019 · External reference
Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway
10.3748/wjg.v17.i31.3605 · 2011 · External reference
Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis
10.1002/smll.201905233 · 2020 · External reference
Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma
10.7150/jca.25909 · 2018 · External reference
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
10.1136/jitc-2019-000317 · 2020 · External reference
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma
10.1016/j.bbrc.2019.08.115 · 2019 · External reference
Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
2018 · External reference
Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma
10.1016/j.yexmp.2019.104265 · 2019 · External reference
Measuring response in solid tumors: comparison of RECIST and WHO response criteria
10.1093/jjco/hyg093 · 2003 · External reference
Reporting results of cancer treatment
10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · 1981 · External reference
Unresolved reference
External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
10.1136/bmj.39489.470347.ad · 2008 · External reference
Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response
10.1177/1534735415596424 · 2016 · External reference
Analysis of sorafenib combined with traditional Chinese medicine decoction in the treatment of advanced primary liver cancer
2018 · External reference
Unresolved reference
External reference
Clinical observation of patients with primary liver cancer treated by sorafenib combined cinobufagin tablets
2012 · External reference
Clinical efficacy of Peiyuan Kangai Decoction with apatinib mesylate tablets for advanced primary liver cancer of spleen-deficiency blood stasis and how to impact on peripheral immune cells and tumor marker
2022 · External reference
Clinical observation on the treatment ofadvanced liver cancer with modified Chaihu Biejia decoction combined with sorafenib
2021 · External reference
Efficacy of Chaihu Shugan Huayu decoction combined with lenvatinib in the treatment of primary liver cancer (Qi stagnation and blood obstruction syndrome)
2022 · External reference
Toxicity, Prognostic Factors and Survival Analysis of Ganji Decoction Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
2020 · External reference
Clinical observation of Huisheng oral liquid combined with lunvatinib in treating advanced liver cancer
2022 · External reference
Effect of Wuzhi tablets on preventing liver injury in patients with primary liver cancer caused by sorafenib
2018 · External reference
Evaluation ofTherapeutic Effect ofQinghuo Tongluo Prescription Combined with Sorafenib on Liver Cancer Based on“Image Thinking”
2018 · External reference
Efficacy of Huazhirougan Granules on Regofinil Targeted Therapy of Middle and Advanced Liver Cancer Patients with Damp Heat Accumulation Type
2022 · External reference
Clinical efficacy of Jianpi Jiedu decoction combined with apatinib mesylate on advanced primary liver cancer
2018 · External reference
Fuzheng Guben therapy improves quality of life in patients with hepatocellular carcinoma on targeted therapy
10.11569/wcjd.v23.i33.5383 · 2015 · External reference
Effect of elemene injection combined with molecular targeting drugs on immunity and survival status of patients with liver cancer metastasis
2022 · External reference
Effect of Jiawei Yiyi decoction combined with apatinib on the efficacy and quality of life of patients with advanced primary liver cancer
2019 · External reference
Clinical study on Huaier Granules combined with sorafenib in treatment of advanced liver cancer
2018 · External reference
Clinical observation of Jianpi Yanggan Jiedu decoction combined with lenvatinib in the treatment of advanced primary liver cancer
2021 · External reference
Curative effect of rosin combine with sorafenib in treatment of patients with moderate and advanced primary liver cancer
2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Effect of Fuling Sini decoction combined with sorafenib on advanced primary liver cancer
2021 · External reference
Unresolved reference
External reference
Clinical Efficacy of Huaier Granule Combined with Sorafenib on Patients with Postoperative Recurrence of Primary Liver Cancer
2019 · External reference
Study on curative effect of Yiqi Huayu Jiedu decoction combined with sorafenib in the treatment of primary hepatocellular caicinoma
2019 · External reference
Clinical observation on the treatment of advanced hepatocellular carcinoma with Sanjia powder combined with sorafenib based on the theory of "master and guest"
2020 · External reference
Unresolved reference
External reference
Systematic evaluation and comparison of statistical tests for publication bias
10.2188/jea.15.235 · 2005 · External reference
Huaier Suppresses the Hepatocellular Carcinoma Cell Cycle by Regulating Minichromosome Maintenance Proteins
10.2147/ott.s279723 · 2020 · External reference
Solanum nigrum Suppress Angiogenesis-Mediated Tumor Growth Through Inhibition of the AKT/mTOR Pathway
10.1142/s0192415x16500713 · 2016 · External reference
Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways
10.1007/s11033-021-06715-0 · 2021 · External reference
Hepatocellular carcinoma
10.1016/s0140-6736(18)30010-2 · 2018 · External reference
Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection
10.1055/s-0039-1677768 · 2019 · External reference
Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
2022 · External reference
Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
10.1186/s12885-021-08043-9 · 2021 · External reference
Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial
10.1053/j.ajkd.2013.05.005 · 2013 · External reference
Uncovering the Mechanism of Astragalus membranaceus in the Treatment of Diabetic Nephropathy Based on Network Pharmacology
2020 · External reference
Traditional Chinese Medicine in Treating Hypertension
10.1161/circoutcomes.121.008723 · 2022 · External reference
Ginsenoside Rg3 for Chemotherapy-Induced Myelosuppression: A Meta-Analysis and Systematic Review
10.3389/fphar.2020.00649 · 2020 · External reference
Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement
10.1001/jama.2017.19163 · 2018 · External reference
Unresolved reference
External reference
Meta-analysis of Traditional Chinese Medicine Combined with Sorafenib in Treatment of Primary Liver Cancer
2020 · External reference
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration
10.7326/m16-2977 · 2017 · External reference
